Grady Sets the Standard For STroke/Neuro care

Stroke Volumes

---

Grady has one of the highest stroke and treatment volumes in the country, treating over 2546 patients in 2023, with the volume continuing to increase.

Stroke Treatment Rates

In 2023, Grady Hospital switched from the intravenous (IV) clot-busting drug Activase to its now preferred Tenecteplase. It administered this drug in 12.6% of stroke cases, above the regional and national average. Our team also performed endovascular treatment (clot retrieval) in 27.2% of stroke cases – almost four times the regional and national average.

Ischemic Stroke Treatment Volumes

This shows the number of patients who not only received the IV clot-busting drug Activase, or Tenecteplase (which replaced Activase in July 2023), at Grady Hospital but also had endovascular clot retrieval at Grady or Activase at an outside hospital before being transferred to Grady for a higher level of care.

Ischemic Stroke Reperfusion

Reperfusion means restoring circulation to a part of the brain blocked by a blood clot in an artery. Grady stroke experts open blocked arteries using endovascular thrombectomy 95.5% of the time, which is above both average regional and national rates.

Nonsurgical Complication Rates

Grady treats more strokes, and our patients experience fewer complications, with rates below the regional and national averages.

Source: American Heart Association /American Stroke Association Get with the Guidelines data, January 2017-December 2023

Nationally Recognized Care

---

In 2011, The Joint Commission designated Grady Health System’s Marcus Stroke and Neuroscience Center as an Advanced Comprehensive Stroke Center, the highest designation available.

In 2025, Grady Hospital again achieved the highest recognition for quality and speed, the American Heart Association/American Stroke Association, Get With The Guidelines® ‒ Stroke Gold Plus, Target Stroke Honor Roll Elite Plus.

In addition to the Gold Plus award, Grady received several other distinctions from the American Heart Association:

• Target: StrokeSM Honor Roll Elite Plus, for reducing the time between hospital arrival and clot-busting treatment.
• Target: StrokeSM Honor Roll Advanced Therapy, for rapid treatment to physically remove clots in eligible patients.
• Target: Type 2 Diabetes™ Honor Roll, for delivering specialized stroke care to patients with Type 2 diabetes, who face a higher risk of complications.